





















## Companion Diagnostics Forum 2020 AGENDA

Tuesday, October 27

10:00 AM	<div>  <div> <p><b>Welcome</b> Oscar Puig, Ph.D. Event Chair Translational Medicine, Oncology Late Stage Development <b>Eli Lilly</b> Ronnye Schreiber CEO <b>PlanetConnect</b></p> </div> <div>  </div> </div>
10:15 AM	<div>  <div> <p><b>KEYNOTE</b> <b>KEYNOTE: Companion Diagnostics: Current Landscape And Future Directions</b> Steve Anderson, Ph.D. Chief Scientific Officer <b>Covance</b></p> </div> <div>  </div> </div>
11:00 AM	<div>  <p><b>BREAK And Meet Your Colleagues!</b></p> </div>
11:30 AM	<div> <p><b>TRACK 1: BIOMARKERS FOR NEUROLOGICAL DISORDERS</b></p> <div>  <div> <p><b>New Frontiers In CNS Blood-Based Biomarkers</b> Andreas Jeromin, Ph.D. Chief Scientific Officer <b>Cohen Veterans Biosciences</b></p> </div> <div>  </div> </div> <div>  <div> <p><b>Biomarkers For Patient Selection And Monitoring Drug Treatments In ALS Clinical Trials</b> Robert Bowser, Ph.D. Chief Scientific Officer <b>Barrow Neurological Institute</b></p> </div> <div>  </div> </div> </div>
12:30 PM	<div>  <p><b>LUNCH BREAK And Discussion Group</b></p> </div>
1:30 PM	<div> <p><b>TRACK 2: NEXT GENERATION BIOMARKERS IN ONCOLOGY</b></p> <div>  <div> <p><b>A Saliva-Based CtDNA Diagnostic For Oral Cancer</b> Radhakrishna Bettadapura Senior Director Business Development <b>Strand Life Science</b></p> </div> <div>  </div> </div> <div>  <div> <p><b>Representative Sampling To Address Tumor Heterogeneity</b> Nelson Alexander, Ph.D. Research Leader <b>Roche Sequencing Solutions</b></p> </div> <div>  </div> </div> <div>  <div> <p><b>NGS-Based Approach Microsatellite Instability Detection Using Tumor Only Sample</b> Wei Ding, Ph.D. Head of Bioinformatics <b>Admera Health</b> Chief Scientific Officer <b>Admera Health, China</b></p> </div> <div>  </div> </div> </div>
3:00 PM	<div>  <p><b>See You Tomorrow At 10:00 AM EST</b></p> </div>

Wednesday, October 28

10:00 AM	<p><b>TRACK 3: TECHNOLOGY AND PLATFORMS</b></p> <div> <div> <p><b>Enabling The Expansive Interrogation Of A Tumor &amp; Its Microenvironment From A Single Sample For Translational Research And Precision Medicine</b>  Christelle Johnson, Ph.D.  Senior Field Applications Scientist  <b>Personalis</b>  Dawn McHugh  Senior Director, Strategic Business Development  <b>Personalis</b></p> </div> <div>  </div> <div>   </div> </div> <div> <p><b>Strategies For Biomarker Screening, Identification, And Validation In Early Stage Translational Research Projects Into Clinical Application</b>  Jacques Corriveau  President &amp; CEO  <b>Ultivue</b></p>  </div>
11:15 AM	<p><b>TRACK 4: COMPANION DIAGNOSTICS DEVELOPMENT</b></p> <div> <p><b>Considerations For Development And Implementation Of A CDx</b>  Karen Richards, RAC  Senior Vice President, In Vitro Diagnostics and Quality  <b>Precision for Medicine</b></p>  </div> <div> <p><b>Key Considerations For Late-Stage Diagnostic Development</b>  Lloye Dillon, Ph.D.  Associate Director, Pharmacodiagnostics  <b>Bristol-Myers Squibb</b></p>  </div>
12:15 PM	<p><b>LUNCH BREAK And Discussion Group</b></p>
1:00 PM	<p><b>TRACK 5: PAIN POINTS AND BARRIERS TO INNOVATION</b></p> <div> <p><b>The Evolving Landscape Of Oncology Clinical Trials: Clinician Perspectives On Drivers And Barriers To Pharmaceutical Innovation</b>  Colin Enderlein  Project Leader  <b>DeciBio</b></p>  </div> <div> <p><b>Update On The Adoption And Utilization Of Emerging Precision Medicine Tools And Technologies In Routine Clinical Care</b>  Andrew Aijian, Ph.D.  Partner  <b>DeciBio</b></p>  </div>
2:00 PM	<p><b>Meet The Speaker - Discussion Group</b></p>
3:00 PM	<p><b>Thank You For Coming!</b></p>

Agenda Version: 10/22/2020, 12:13:39 PM